Antimicrobial resistance (AMR) is a top 10 global health threat, expected to kill more than 10 million people annually by 2050. As bacteria become resistant to current antibiotics, these antibiotics become less and less effective at fighting infections. The result is that even routine surgeries and common infections can become deadly – from cancer, urinary tract infections, and pneumonia to C-sections, hip replacements, and root canals –threatening to reverse the progress that has brought about our unprecedented longevity. This session will examine innovative financing options to ensure we continue to invest in a pipeline of antibiotics to tackle AMR.